Torsdag 26 December | 14:06:22 Europe / Stockholm

Kalender

Tid*
2025-03-06 N/A Kvartalsrapport 2025-Q2
2024-11-11 - X-dag ordinarie utdelning HEALTH 0.00 EUR
2024-11-08 - Årsstämma
2024-09-20 - Bokslutskommuniké 2024
2024-03-07 - Kvartalsrapport 2024-Q2
2023-11-17 - X-dag ordinarie utdelning HEALTH 0.00 EUR
2023-11-16 - Årsstämma
2023-09-28 - Bokslutskommuniké 2023
2023-04-24 - Extra Bolagsstämma 2023
2023-03-23 - Kvartalsrapport 2023-Q2
2022-11-17 - Årsstämma
2022-10-25 - X-dag ordinarie utdelning HEALTH 0.00 EUR
2022-09-29 - Bokslutskommuniké 2022
2022-06-29 - Extra Bolagsstämma 2022
2022-02-24 - Kvartalsrapport 2022-Q2
2021-10-29 - X-dag ordinarie utdelning HEALTH 0.00 EUR
2021-10-28 - Årsstämma
2021-09-15 - Bokslutskommuniké 2021

Beskrivning

LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriMedicinteknik
Nightingale Health är verksamt inom medicinteknik. Bolaget är specialiserat inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar plattformar och tjänster inom blodanalyser som används i sjukdomsförebyggande syfte. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs globalt med störst närvaro inom Europa.
2021-06-23 08:30:00

Company Release

23 June 2021 at 9:30 a.m. (Finnish time)

Nightingale Health Oyj ("Nightingale") announced in February 2021 an early-access pilot of its at-home blood testing solution for 10,000 consumers in Finland.

As planned, the first phase of the pilot began in the second quarter of 2021 by providing consumers the opportunity to be the first users of Nightingale's at-home testing solution. After opening registration, the at-home blood collection kit orders exceeded quickly the maximum number of participants for the first phase, and blood samples collected at home were shipped for analysis to Nightingale's laboratory within June 2021. 

Due to strong interest by consumers, Nightingale will launch the second phase of the at-home blood testing pilot in July 2021. The pilot will consist in total of three phases, and all phases are estimated to be completed by the end of 2021 in accordance with the original schedule. 

Nightingale considers the successful launch of the at-home blood testing pilot as a major achievement, as enabling the blood collection at customers' homes provides a logistically efficient solution to expand the availability of Nightingale's technology rapidly to the global market.

For further information, please contact:

Teemu Suna, CEO
ir@nightingalehealth.com

Certified Adviser:
Oaklins Merasco Ltd, tel. +358 9 6129 670

About Nightingale

Nightingale Health is a health technology company transforming preventive care. We envisage a world that focuses on keeping people healthy rather than just treating illnesses. By combining our pioneering blood-testing technology and the ability to detect future disease risks, we are creating a world-leading health data platform that enables preventative care with better information. The platform helps people make better personal health decisions and connects the health industry to offer their services for individuals' preventative needs. By empowering the world with comprehensive health insights, we accelerate scientific discoveries, industry developments and improve personal health for everyone.